Woodside Rationalises Global Portfolio With Calypso Divestment

HOUSTON--(BUSINESS WIRE)-- Woodside has entered an agreement to sell its 70% operated interest in production sharing contract TTDAA 14 (‘Calypso Project’) in Trinidad and Tobago to bp.

bp currently holds the remaining 30% interest in the project and has an established upstream presence in Trinidad and Tobago.

Woodside Chief Executive Officer Liz Westcott said the Calypso Project divestment further simplified Woodside's portfolio and supported the company's disciplined approach to capital allocation.

"The transaction demonstrates Woodside’s clear focus on progressing the right opportunities across our global portfolio that have the best potential to deliver sustained value for Woodside shareholders.

“Completion of the divestment will conclude Woodside's decades-long presence in Trinidad and Tobago that has included interests in the Ruby and Angostura offshore oil and gas field operations and associated production facilities.

"We thank the Government of Trinidad and Tobago, our joint venture participants and all those who have supported our business in the country over such a long period.”

The transaction, comprising both cash consideration and contingent payments, is expected to close by the end of 2026. Completion of the transaction is subject to customary conditions precedent, including government and regulatory approvals.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260805075498/en/

Media contacts
Australia
Christine Abbott
M: +61 484 112 469
E: [email protected]

United States
Rob Young
M: +1 281 790 2805
E: [email protected]

Source: Woodside Energy

You May Also Be Interested In

• Simplify Healthcare Names Kamal Ahuja Chief Growth Officer to Accelerate Expansion of Its Payer AI Platform
• Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats
• Choose Health Launches Most Comprehensive At-Home Liver Function Test with 20+ Biomarkers and Clinical Risk Scores